Metal protein attenuating compounds for the treatment of Alzheimer's dementia

Abstract

Cherny 2001 Cherny RA, Atwood CS, Xilianas ME, et al.Treatment with copper-zinc chelator markedly and rapidly inhibits ß-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001;30:665-76.

Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews

“…An additional 10 reviews were identified that listed ADL as an outcome of interest; however the reviews failed to identify any applicable studies. These reviews were for socially assistive robots, animal-assisted therapy, transcutaneous electrical nerve stimulation, social support groups for the person with dementia, naftidrofuryl, respite care, smart home technologies, metal protein-attenuating compounds, ibuprofen and educational interventions for the person with dementia 36–45. One review evaluated the efficacy of metrifonate, however identified serious harms associated with use; metrifonate was since withdrawn from the market 46.…”

Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews

“…An additional 10 reviews were identified that listed ADL as an outcome of interest; however the reviews failed to identify any applicable studies. These reviews were for socially assistive robots, animal-assisted therapy, transcutaneous electrical nerve stimulation, social support groups for the person with dementia, naftidrofuryl, respite care, smart home technologies, metal protein-attenuating compounds, ibuprofen and educational interventions for the person with dementia 36–45. One review evaluated the efficacy of metrifonate, however identified serious harms associated with use; metrifonate was since withdrawn from the market 46.…”

A 2-Substituted 8-Hydroxyquinoline Stimulates Neural Stem Cell Proliferation by Modulating ROS Signalling

“…clioquinol [54]). Some of these considerations may explain why clioquinol and 5,7-dichoro-DMAMQ have not shown evidence of clinical benefit in treating AD [55].…”

Prenatal Zinc Deficient Mice as a Model for Autism Spectrum Disorders

“…Based on these results, control of local zinc concentrations at synapses through zinc transporters may be a promising approach, and synaptic zinc transporters an interesting drug target. Further, metal protein attenuating compounds (MPACs) that have been proposed for the treatment of cognitive impairment due to Alzheimer’s dementia [ 141 , 175 ] may show beneficial effects in ASD. Unfortunately, to our knowledge, these drugs have not been investigated in ASD mouse models or human patients so far, although MPACs such as PBT2 have been proven safe and tolerable in humans in clinical trials ( Figure 3 ).…”

Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews

“…An additional 10 reviews were identified that listed ADL as an outcome of interest; however the reviews failed to identify any applicable studies. These reviews were for socially assistive robots, animal-assisted therapy, transcutaneous electrical nerve stimulation, social support groups for the person with dementia, naftidrofuryl, respite care, smart home technologies, metal protein-attenuating compounds, ibuprofen and educational interventions for the person with dementia 36–45. One review evaluated the efficacy of metrifonate, however identified serious harms associated with use; metrifonate was since withdrawn from the market 46.…”

A 2-Substituted 8-Hydroxyquinoline Stimulates Neural Stem Cell Proliferation by Modulating ROS Signalling

“…clioquinol [54]). Some of these considerations may explain why clioquinol and 5,7-dichoro-DMAMQ have not shown evidence of clinical benefit in treating AD [55].…”

Prenatal Zinc Deficient Mice as a Model for Autism Spectrum Disorders

“…Based on these results, control of local zinc concentrations at synapses through zinc transporters may be a promising approach, and synaptic zinc transporters an interesting drug target. Further, metal protein attenuating compounds (MPACs) that have been proposed for the treatment of cognitive impairment due to Alzheimer’s dementia [ 141 , 175 ] may show beneficial effects in ASD. Unfortunately, to our knowledge, these drugs have not been investigated in ASD mouse models or human patients so far, although MPACs such as PBT2 have been proven safe and tolerable in humans in clinical trials ( Figure 3 ).…”

Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews

“…An additional 10 reviews were identified that listed ADL as an outcome of interest; however the reviews failed to identify any applicable studies. These reviews were for socially assistive robots, animal-assisted therapy, transcutaneous electrical nerve stimulation, social support groups for the person with dementia, naftidrofuryl, respite care, smart home technologies, metal protein-attenuating compounds, ibuprofen and educational interventions for the person with dementia 36–45. One review evaluated the efficacy of metrifonate, however identified serious harms associated with use; metrifonate was since withdrawn from the market 46.…”

A 2-Substituted 8-Hydroxyquinoline Stimulates Neural Stem Cell Proliferation by Modulating ROS Signalling

“…clioquinol [54]). Some of these considerations may explain why clioquinol and 5,7-dichoro-DMAMQ have not shown evidence of clinical benefit in treating AD [55].…”

Prenatal Zinc Deficient Mice as a Model for Autism Spectrum Disorders

“…Based on these results, control of local zinc concentrations at synapses through zinc transporters may be a promising approach, and synaptic zinc transporters an interesting drug target. Further, metal protein attenuating compounds (MPACs) that have been proposed for the treatment of cognitive impairment due to Alzheimer’s dementia [ 141 , 175 ] may show beneficial effects in ASD. Unfortunately, to our knowledge, these drugs have not been investigated in ASD mouse models or human patients so far, although MPACs such as PBT2 have been proven safe and tolerable in humans in clinical trials ( Figure 3 ).…”